Evidence map›Paper›PMID 27544285›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Matthew P Mulé, Gabriel N Mannis, Brent L Wood, Jerald P Radich, Jimmy Hwang, Nestor R Ramos, Charalambos Andreadis, Lloyd Damon, Aaron C Logan, Thomas G Martin and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. [Advances in autologous stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
    Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Matthew P MuléMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Gabriel N MannisDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Brent L WoodFred Hutchinson Cancer Research Center, Seattle, Washington.
Jerald P RadichFred Hutchinson Cancer Research Center, Seattle, Washington.
Jimmy HwangDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Nestor R RamosMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Charalambos AndreadisDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Lloyd DamonDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Aaron C LoganDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Thomas G MartinDepartment of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, California.
Christopher S HouriganMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: hourigan@nih.gov.
University of California, San Francisco · USNational Institutes of Health · USFred Hutch Cancer Center · US

Funding

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0M
Understanding and predicting relapse in acute myeloid leukemiaR01CA175008 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RADICH, JERALD PATRICK · 2013 to 2023
$3.9M
Intramural NIH HHS ZIA HL006163NCI NIH HHS R01 CA175008
6 · The paper itself

Abstract

We report here the largest study to date of adult patients with acute myeloid leukemia (AML) tested for measurable residual disease (MRD) at the time of autologous hematopoietic cell transplantation (auto-HCT). Seventy-two adult patients who underwent transplantation between 2004 and 2013 at a single academic medical center (University of California San Francisco) were eligible for this retrospective study based on availability of cryopreserved granulocyte colony-stimulating factor (GCSF)-mobilized autologous peripheral blood progenitor cell (PBPC) leukapheresis specimens ("autografts"). Autograft MRD was assessed by molecular methods (real-time quantitative PCR [RQ-PCR] for Wilms tumor 1 (WT1) alone or a multigene panel) and by multiparameter flow cytometry (MPFC). WT1 RQ-PCR testing of the autograft had low sensitivity for relapse prediction (14%) and a negative predictive value of 51%. MPFC failed to identify MRD in any of 34 autografts tested. Combinations of molecular MRD assays, however, improved prediction of post-auto-HCT relapse. In multivariate analysis of clinical variables, including age, gender, race, cytogenetic risk category, and CD34

Indexed as

Predictive Value of TestsAdultAgedAutograftsFemaleFlow CytometryGenes, Wilms TumorHematopoietic Stem Cell TransplantationHumansLeukapheresisLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm, ResidualPolymerase Chain ReactionRecurrenceAcute myeloid leukemiaAutologous hematopoietic cell transplantationMeasurable residual disease

Identifiers

PMID27544285
PMCPMC5072749
OpenAlexW2517891960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.